Edmundo José Velasco Martinelli
Research Subjects
Edmundo José Velasco Martinelli has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ana Vega Carreiro de Freitas
Hospital das Clínicas Faculdade de Medicina Universidade de São Paulo São Paulo SP Brazil Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
1 shared publication - Bernardo Kaplan Moscovici
Department of Ophthalmology and Visual Sciences, Universidade Federal de São Paulo, São Paulo, Brazil; Postgraduate Program in Translational Medicine, Department of Medicine, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil; Department of Ophthalmology, Laser Vision Hospital, Santos, São Paulo, Brazil
1 shared publication - Daniella Villas Boas Fairbanks1 shared publication
Fernando Antonio Galhardo Tarcha
1 shared publication- Luís Gustavo de Imparato Rodrigues Ribeiro1 shared publication
- Natália Fernandes Gonçalves Napolitano1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by GN1 Sistemas e Publicacoes Ltd. in Arquivos Brasileiros de Oftalmologia
- Vol. 89 (3) , 1-8
Diluted brimonidine for improving early postoperative symptoms and subconjunctival hemorrhage after PRK and LASIK
Purpose: To assess whether low-concentration brimonidine (0.025%) improves early postoperative signs and symptoms following femtosecond laser-assisted in situ keratomileusis and photorefractive keratectomy without affecting pupil diameter or flap safety. Methods: This prospective, randomized, double-masked, contralateral-eye, single-center study was conducted between January and September 2024. In each patient, one eye received 0.025% brimonidine 15–30 min before surgery (mean: 21.3 ± 2.4 min), whereas the fellow eye received 0.15% sodium hyaluronate (control). Primary outcomes on postoperative Day 1 included subconjunctival hemorrhage laser-assisted in situ keratomileusis and patient-reported symptoms (0–10 scale; composite score). Pupil diameter was measured pre-ablation. Statistical analyses included McNemar and paired t tests, with a significant threshold of α=0.05. Results: A total of 124 patients were included (54 laser-assisted in situ keratomileusis and 70 photorefractive keratectomy). Pupil diameter did not differ significantly between brimonidine-treated and control eyes (laser-assisted in situ keratomileusis: 2.63 ± 0.47 vs. 2.69 ± 0.42 mm, p=0.273; photorefractive keratectomy: 2.56 ± 0.44 vs. 2.61 ± 0.39 mm, p=0.116). In laser-assisted in situ keratomileusis, subconjunctival hemorrhage occurred less frequently in brimonidine-treated eyes both intraoperatively (9.3% vs. 46.3%, p<0.001) and on postoperative Day 1 (9.3% vs. 50.0%, p<0.001). Composite symptom scores were significantly lower in brimonidine-treated eyes in both laser-assisted in situ keratomileusis and photorefractive keratectomy groups (p=0.001 for both). Conclusions: Preoperative administration of low-concentration brimonidine (0.025%) significantly reduced subconjunctival hemorrhage in laser-assisted in situ keratomileusis without comprising flap integrity. It also improved early postoperative symptoms in laser-assisted in situ keratomileusis and photorefractive keratectomy, without affecting pupil diameter. These findings support the use of dilute brimonidine as a safe and effective adjunct to enhance the immediate postoperative experience in refractive surgery.
- 1 January 2026
- Published by GN1 Sistemas e Publicacoes Ltd. in Arquivos Brasileiros de Oftalmologia
- Vol. 89 (3) , 1-8
Open AccessDiluted brimonidine for improving early postoperative symptoms and subconjunctival hemorrhage after PRK and LASIK
Purpose: To assess whether low-concentration brimonidine (0.025%) improves early postoperative signs and symptoms following femtosecond laser-assisted in situ keratomileusis and photorefractive keratectomy without affecting pupil diameter or flap safety. Methods: This prospective, randomized, double-masked, contralateral-eye, single-center study was conducted between January and September 2024. In each patient, one eye received 0.025% brimonidine 15–30 min before surgery (mean: 21.3 ± 2.4 min), whereas the fellow eye received 0.15% sodium hyaluronate (control). Primary outcomes on postoperative Day 1 included subconjunctival hemorrhage laser-assisted in situ keratomileusis and patient-reported symptoms (0–10 scale; composite score). Pupil diameter was measured pre-ablation. Statistical analyses included McNemar and paired t tests, with a significant threshold of α=0.05. Results: A total of 124 patients were included (54 laser-assisted in situ keratomileusis and 70 photorefractive keratectomy). Pupil diameter did not differ significantly between brimonidine-treated and control eyes (laser-assisted in situ keratomileusis: 2.63 ± 0.47 vs. 2.69 ± 0.42 mm, p=0.273; photorefractive keratectomy: 2.56 ± 0.44 vs. 2.61 ± 0.39 mm, p=0.116). In laser-assisted in situ keratomileusis, subconjunctival hemorrhage occurred less frequently in brimonidine-treated eyes both intraoperatively (9.3% vs. 46.3%, p<0.001) and on postoperative Day 1 (9.3% vs. 50.0%, p<0.001). Composite symptom scores were significantly lower in brimonidine-treated eyes in both laser-assisted in situ keratomileusis and photorefractive keratectomy groups (p=0.001 for both). Conclusions: Preoperative administration of low-concentration brimonidine (0.025%) significantly reduced subconjunctival hemorrhage in laser-assisted in situ keratomileusis without comprising flap integrity. It also improved early postoperative symptoms in laser-assisted in situ keratomileusis and photorefractive keratectomy, without affecting pupil diameter. These findings support the use of dilute brimonidine as a safe and effective adjunct to enhance the immediate postoperative experience in refractive surgery.